Back to search

Peptide record

TPDB41055

IL-1 Anticancer standard
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41055
IL-1
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 16-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
FKAGGFIKKLWRSLLA
Physicochemical Analysis
C90H143N23O18
NDCEQHMPTYV
LK
1835.27
11.73
4
0
9
+4
-2.51
0.400
110.00
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
5500
299.68
1
Residue Composition
number
2
A
1
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
1
I
3
L
3
K
0
M
2
F
0
P
1
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 1 L: 3 K: 3 M: 0 F: 2 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
16
C90H143N23O18
1835.27
11.73
+4
-2.51
0.400
Free
L
Linear
Free
Anticancer
Synthetic Mutant form of ZXR-II
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 73.9 ± 13.6 µM
Anticancer
73.9

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT assay
4-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2017

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 58.4 ± 13.7 µM
Anticancer
58.4

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
4-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2017
Evidence 3 Activity

Activity

30% LDH release at 32 µM
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

LDH leakage assay
2-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2017